Use of imp3 as a prognostic marker for cancer
AssigneeUniversity of Massachusetts
InventorZhong Jiang
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided.
Claims20
A method for treating a subject having renal cell carcinoma (RCC) or bladder carcinoma, comprising the steps of:
- (a) obtaining from the subject a primary tumor tissue of the kidney or bladder;
- (b) determining the presence or level of IMP3 in a primary tumor and (c) treating the subject for metastasis if the primary tumor expresses IMP3.
A kit comprising an agent for detecting the presence or level of IMP3 and a control IMP3 value.
A method for monitoring the progression of cancer in (RCC) or a bladder carcinoma in a subject, comprising monitoring the presence or level of IMP3 in a primary tumor of the subject over time, wherein an increase in the level of IMP3 in the primary tumor of the subject indicates that the cancer is progressing.
Dependencies are inferred from the claim text.